Long‑Acting Injectable Anesthetic Formulations for Severe and Pathological Pain (Injectable Formulations of Anesthetics for any Pathological Pain, Tech ID: 18‑039)
Technology Overview: This NJIT technology provides injectable anesthetic formulations engineered for extended analgesia in severe or pathological pain conditions. By optimizing drug composition and release kinetics, the formulation maintains therapeutic levels over clinically meaningful durations while minimizing systemic exposure. The platform is compatible with established administration techniques and can be tailored for perioperative, neuropathic, or cancer‑related pain management.
Industry Pain Point: Short‑acting anesthetics require frequent dosing, increasing side effects and care burden.
NJIT Solution: A long‑acting injectable that sustains analgesia and reduces dosing frequency.
Key Features & Advantages
- Prolonged analgesic effect with controlled release
- Reduced systemic exposure and dosing frequency
- Tailorable profiles for multiple pain indications
- Compatible with standard injection workflows
Development Stage: TRL 4–5 – Preclinical validation of release and efficacy.
Target Markets
- Perioperative and postoperative pain
- Neuropathic and cancer pain
- Interventional pain management
Market Opportunity
- Global pain management drugs/devices (2026): ~$90B
- CAGR: ~6–7%
- 2035 projection: ~$160–170B
Commercial & IP Details
Inventors: Xiaoyang Xu, Yuanxiang Tao